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Abstract 
Smoking represents a worldwide problem and affects various body functions. The present study 
was conducted to evaluate the available concentration of some clotting factors in smokers 
polycythemic male patients. A total number of subjects was 120, 80 smokers males were affected with 
polycythemia and the remainders 40 males were healthy and served as a control group. The 
polycythemic patients were subdivided into two groups according to their ages (first group ranged 
between 30-40 years old and the second group ranged between 41-50 years old). PCV, clotting factor 
(FI, FVII and FVIII) were detected. The results of present study indicated that the levels of 
prothrombin time (PT) and activated partial thromboplastine time (APTT) were significantly increased 
(p˂ 0.05) in both groups of polycythemia in comparison with control group. Regarding concentration 
of fibrinogen factor (FI) and serum prothrombin conversion accelerator factor (FVII) were elevated (P˂ 
0.05) in both groups and pointed  out a positive correlation (r = 0.437, r = 0.378, respectively) with 
packed cell volume (PCV) when compared with those of control group. On the other hand, 
concentration of antihemophilic factor (FVIII) recorded a significant fall (p˂ 0.05) in both tested 
groups and indicated a low correlation (r = 0.292). The possible explanation to the changes mentioned 
above is based on the fact that confirm smoking is a dangerous material containing different toxic 
substances that affect the vital organs of the body and induce abnormalities of hemostatic mechanism.      
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ةصلاخلا 
  مييقتل ةيلاحلا ةساردلا تممص .مسجلا فئاظو فمتخم ىمع وتاريثأت للاخ نم راشتنلاا ةعساو ةيملاع ةمكشم نيخدتلا لثمي
 ىدل رثختلا لماوع ضعب زيكارتلاجرلا  طرف ةلاحب نيباصملا و نينخدملاتايرك مدلا  .رمحلا تممش  ةساردلا021 لاجرً ,01  مينم
رمحلا تايركلا طرفب نيباصمو نينخدم اوناك  ددعلا ناك نيح يفيقبتملا 01 لاجرً مى .نيباصم ريغ ءاحصا  صاخشلاا مسق
 نيباصملااقبط   مىرامعلأ  نيب تحوارت ىلولاا ةئفلا ,نيتيرمع نيتئف ىلا01-01  نيب تحوارت ةيناثلا ةئفلاو ةنس00-01 .ةنس 
( ايونعم اعافترا ةساردلا جئاتن تريظأp< 0.05 نيبمورثوربلا نمز نم لك ميق يف )PT  نمزونيتسلابوبمورثلا  ايئزج لعفملاAPTT 
 .ءاحصلاا صاخشلاا عم ايتنراقم دنع نيتئفلا لاك يف( يونعم عافترا لوصح ظحول دقف رثختلا لماوع زيكارت صوصخبوp<0.05 )
( نيجونيربيافلا نم لك ميق يفFI( نيبمورثوربلا ليوحت عرسم لماع ميقو )FVII ميق عم ابجوم اطابترا اققح دقو نيتعومجملا لاك يف )
( طوغضملا ايلاخلا مجحPCV( )r = 0.437, r = 0.376حول نيح يف .يلاوتلا ىمع ) لماعلا ميق يف يونعم ضافخنا لوصح ظ
( فزنمل داضملاFVIII( هرادقم طوغضملا ايلاخلا مجح عم اطابترا ققحو نيتئفلا لاك ىدل )r = 0.292 يف ةحضوملا تاريغتلا نا .)
تلاو ةيلاع ةيمس تاذ داوم ىمع وئاوتحلا مسجلا ىمع ةراض تاريثأت نيخدتمل نا ىلا ةسيئر ةروصب ىزعت نا نكمي هلاعا رثؤت اىرودب ي
 نازتلاا تايممع يف ةصاخ ةيفيظو تابارطضا لوصح ىلا ةيدؤم مسجمل ةيويحلا ءاضعلاا ىمع يومدلا. 
 :ةيحاتفملا تاممكلانيخدتلا ,رثختلا لماوع ,رمحلا تايركلا طرف 
Introduction 
Polycythemia is considered as a heightening in packed red cell volume resulted 
from various  pathological states and stimulaters that  may or may not be related  with 
a rise in red cell mass (RCM) (Pearson and Messinezy, 1996). A cigarette smoker 
become exposed to a number of toxic substances such as nicotine, oxidative stress, 
carbon monoxide and various amount of gaseous products (Gitte, 2011). In fact, 
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tobacco cigarette smoking has been identified as one of the major death causes 
(Kumar et al., 2009). It is familiar that smokers have higher risk factor for 
hypertension, cardiovascular events, strock , inflammation,  clotting disorder, and 
respiratory disease (Tiel et al., 2002 ; Abel et al., 2005). 
 Many coagulation protein elements are involved in reaction steps that produce 
the hemostatic process. Absence in any of the coagulator protein elements can lead to 
continuous bleeding.  (Ogedegbe, 2002). Hemostasis  is commonly managed by three 
essential components particularly, the vascular wall, platelets, and the coagulation  
factors (Kumar et al., 2005). Few studies are available on alteration in hemostasis of 
smoker humans, especially in plasmatic hemostasis. Some of laboratory indices of 
hemostasis processes are believed to be affected by smoking. There are several 
reports showing markers of suppressed fibrinolysis by drop tissue – type plasminogen 
activator and regulated up plasminogen activator inhibitor – 1  concentration. 
Moreover, heightened fibrinogen concentration and suppressed amounts of protein C 
and activated protein C have been explained. These alterations can be returned to 
endothelial injured and then inflammatory process (Yanbaeva et al., 2007; Al-
Sweedan et al., 2010).  
 
Methods and Materials 
Subjects of  study: 
The present study was carried out throughout the period ranged between October  
2014 to August  2015,  in blood bank of  Babylon and laboratories of college of 
sciences for women in Babylon university. The total number of subjects was (120) : 
polycythemic smoking  patients for a period at least 5 years ago and healthy men. 
Eighty (80) men were smokers and affected with polycythemia and those have PCV 
more than 50%. The remaining number (40) were normal healthy men and non-
smokers. The smoker polycythemic males were consequently subdivided according to 
their ages into two groups (First group was 30-40 years old and the second group was 
41-50 years old). All subjects of  the study were free from other chronic diseases such 
as diabetes mellitus, thyroid disorders, cardiovascular disease, and renal disturbance. 
These data were obtained by questioner. All patients attend to blood bank to perform 
phlebotomy to normalize PCV. The ages of healthy subjects were ranged between 20- 
50 years old. 
 
Coagulation factors assay 
1- Prothrombin time (PT), partial thromboplastin time (PTT) and fibrinogen 
concentration were determined  according to the procedure of the kits of (BioLabo 
SA, France). 
2- Factor VII, factor FVIII concentrations were determined according to the procedure 
of the kits of (Elabscience Biotechnology) 
  
Statistical analysis 
All values were expressed as means ± stander deviation (S.D). The data has been 
analyzed by using computer SPSS program. Studentʹs t-test has been used to examine 
the differences among different groups and p˂ 0.05 was used as lowest significant 
limit (Daniel, 1999). 
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The results 
1: Packed cell volume  (PCV) 
The  results  of  PCV in (table 1) point out a significant elevation  (p< 0.05) in 
both tested  groups of  polycythemia (53.65 ± 2.49, 52.33 ± 2.99  %, respectively), in 
compare with control  group (44.94 ± 1.1 %). 
 
2: Prothrombin time (PT) 
The results of  PT explained in (table 1) show a significantly increase (p< 0.05) in 
both groups of  smokers males affected with polycythemia (15.41± 1.88, 15.23 ± 1.45 
second, respectively), ), in compare with control  group (13.23 ± 0.42 second). 
 
3: Activated partial thromboplastin time (APTT) 
There is a significant elevation (P< 0.05) in APTT values for two groups of  
smokers'  polycythemia  (23.15 ± 1.15, 22.89 ± 1.06 second, respectively) as shown in 
(table 1), ), in compare with control group (20.42 ±  0.66 second). 
 
4: Fibrinogen concentration (FI) 
The results of  fibrinogen concentration illustrated in (table 1) show a significant 
increase  (p˂ 0.05) in the first and second group of  polycythemic smokers (324.88 ± 
40.25, 351.74 ± 41.52 mg/L, respectively), in compare with control group (277.4 ± 
33.98 mg/L). The results of correlation between values of  PCV and  FI which have 
been shown in figure (1) revealed a positive correlation (r= 0.437). 
 
Table 1: Means of  packed cell volume (PCV %), prothrombin time (PT second), 
activated partial thromboplastin time (APTT second), fibrinogen concentration 
(mg/L) ) of  healthy control  group  and  two groups of smoker males suffering from  
polycythemia. 
Groups 
 
 
Parameters 
Healthy control 
group      n = 40 
    Smokers' polycythemic groups           
       n = 40 
 20-30 years (First group) 
  30-40 years 
(Second group)  
41-50 years 
PCV (%) 44.94 ± 1.1 53.65* ± 2.49 52.33* ± 2.99 
PT (second) 13.23 ± 0.42 15.41* ± 1.88 15.23* ± 1.45 
PTT (second) 20.42 ± 0.66 23.15* ±1.15 22.89* ± 1.06 
Fibrinogen(mg/L) 277.4 ± 33.98 324.88* ± 40.25 351.74* ± 41.52 
-Values are mean ± SD                                  
- Means with asterisk * are significantly different at p < 0.05                                          
- n = number of males in one group
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Figure 1: Correlation between fibrinogen concentration (mg/L) and packed cell 
volume (PCV %) of control group and two groups of polycythemic smokers. 
5: Serum prothrombin conversion accelerator (Factor VII) concentration 
(pg/mL) 
The findings of  factor VII concentration elucidated in figure (2) indicate  a 
significant increase (p< 0.05) in both groups of polycythemic smokers (316.27 ± 
155.33, 298.92 ± 112.41 pg/mL, respectively), in compare with control group (197.33 
± 99.89  pg/mL). The results of correlation between PCV values and factor VII 
indicate a positive correlation ( r = 0.382) as indicated in figure (3). 
Figure 2: Means of serum prothrombin conversion accelerator factor (Factor VII 
pg/mL ) of  healthy  group  and  two groups of  smokers males affected with 
polycythemia. 
-Values are mean ± SD                                                                                           
- Means with asterisk * are significantly different at p < 0.05                                              
- n= number of males in one group 
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Figure 3: Correlation between  serum prothrombin conversion accelerator (Factor VII 
pg/ml ) and packed cell volume (PCV) of  control group and two groups of 
polycythemic smokers. 
6: Anti-hemophilic factor (Factor VIII ) concentration (pg/ml) 
The results of  factor VIII concentration in figure (4) have been appeared 
markedly drop (p< 0.05) in two groups of  smokers' polycythemia (0.761 ± 1.16, 
0.894 ± 2.11 pg/mL, respectively), when compared to that of healthy control group 
(3.36 ± 4.11 pg/mL). The results of correlation between PCV values and factor VIII 
concentration show a positive correlation (r = 0.017) as described in figure(5).
Fig.4: Means of  anti-hemohpilic factor (Factor VIII pg/mL ) of  control  group  and 
two groups of polycythemic smokers. 
-Values are mean ± SD                                                                                                     
-Means with asterisk * are significantly different at p < 0.05                                          
- n= number of males in one group 
3.36±4.11 
0.761*±1.16 0.894*±2.11 
0
0.5
1
1.5
2
2.5
3
3.5
4
 (20-30) years
Healthy group
  (30-40) years
First group
 (41-50) years
Second groupF
ac
to
r 
V
II
I 
co
n
ce
n
tr
at
io
n
 (
p
g/
m
L)
 
Smokersʼ polycythemia 
n = 40
0
100
200
300
400
500
600
700
0 10 20 30 40 50 60
Fa
ct
o
r 
V
II
 c
o
n
ce
n
tr
at
io
n
 p
g/
d
L 
Packed cell volume % 
R=0.382 
Journal of University of Babylon, Pure and Applied Sciences, Vol.(25), No.(5), 2017. 
4761 
 
Figure 5: Correlation between anti-hemophilic factor (Factor VIII pg/mL ) and 
packed cell volume (PCV) of control group and two groups of  polycythemic 
smokers.  
 
Discussion 
1:Prothrombin time (PT) and activated partial thromboplastin time (APTT) :  
The results of present study appear a significantly increase (P< 0.05) for PT and 
APTT in  both groups of polycythemic smokers  in compare with those of control 
group. Previous study showed that hematocrits are more than 55% because of the 
possibility of  longtime of routine coagulation test (PT, aPTT) (Austin et al., 2013). 
Many studies confirmed that samples from subjects with maximum hematocrit 
(>55%) may result in increasing time of  PT and aPTT (Marlar et al., 2006 ; Hood and 
Eby, 2008).  
The facts which have been explained previously showed that prolonged smoking 
triggers hemostatic disorder producing from continuous smoking. Although the 
persons were generally influenced where those who have smoked for duration about 
12 years and above, PT where changed even in those who have smoked for only 2 
years. (Ngozi and Ernest, 2014). One can hypothesize that prolonged time of PT and 
APTT in this study may return to effects of smoking on extrinsic and intrinsic 
pathways of coagulation, since, it may be either increased concentration and activity 
of some clotting factors or decreased the activity of other that might implicated in 
prolongation of  PT and APTT. As explained from the data of FVIII, there is a 
decrease of FVIII that may be implicated in delay of intrinsic pathway. 
2: Fibrinogen factor (FI): 
  The results which have been obtained from the present study referred to a 
significant elevation (P< 0.05) of fibrinogen in two groups of polycythemic smokers 
when compared with control group. These data agree with the following study, which 
recognized that fibrinogen concentration are more in smokers than non-smokers, and 
it had been documented that the progression dangerous of cardiac arrest in heavy 
smokers might be related with increase fibrinogen concentration through arterial wall 
deposition and effects on HCT, platelet aggregation and adhesive, blood viscosity and 
fibrin production, significant marker for increased fibrinogen concentration in the 
heavy smokers can be observed in the recorded short time seen in the coagulation 
indicators (Danesh et al., 2000 ; Ngozi and Ernest, 2014). In healthy males who were 
smoking for 5 years or more, further, smoking is related with 22% minimum clot 
permeability and 35% longer clot lysis compared with never smokers. These 
observations of smoking-related fibrin changes seem to be estimated largely by 
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increased fibrinogen and accelerated oxidative stress (OS) (Undas et al., 2009). The 
present results conflict with fact that illustrate fibrinogen protein is especially 
subjected to oxidation, ≈20% higher than of albumin. So that fibrinogen may also 
relief a free radicals and impair other proteins from exposure to oxidation. Fibrinogen 
oxidation subsequently exposure to oxygen, metal, and myeloperoxidase-derived 
oxidants drop the rate of clot develop (Olinescu and Kummerow, 2001). From the 
facts mentioned above, one can suggest that smoking induce inflammatory reactions 
and oxidative stress that acts together to increase production of fibrinogen by 
hepatocytes. 
3:Serum prothrombin conversion accelerators factor (FVII): 
The results of present study document a significant increase (P< 0.05) of factor 
VII concentration in both groups of smokers' polycythemia when compared with 
healthy control group. This study agrees with the previous studies revealed that 
cigarette smoking is consider one of the main carcinogenic agents because of 
chemical elements that stimulate the liberation of free radicals (oxidative-stress), drop 
prostacyclin release causing to clot production, as well as increased production of 
fibrinogen (FI) and coagulative factor VII (Butkiewicz et al., 2006 ; Padmavathi et 
al.,  2010). Also, a study of McBride (1992),  documented an increased factor VII 
activity in smokers. It is well known that smoking activates a hypercoagulable state of 
the blood, but its effect on plaque thrombogenicity is not understood and the 
researches indicate  that tissue factor (TF) plays an essential role in thrombus 
production after plaque disruption (Toschi et al., 1997). Other study indicate that 
smoking elevates the plasma level of fibrinogen but seems to have lower effect on the 
level of factor VII (Powell, 1998). The present data were inconsistent with Delgado et 
al. (2015), which confirmed that there was a drop in level of factor VII (included in 
the activation of extrinsic clotting cascade). The present data may be attributed to the 
fact that smoking stimulates activity of clotting factor VII and because of tissue 
damage may increase levels of tissue factor (TF). 
4: Anti – hemophilic factor (Factor VIII) : 
The results of  factor VIII concentration in the present study showed a significant 
drop (P< 0.05) in both polycythemic smoker groups when compared with those of 
control group. Previous study explained the effect of smoking on the clotting 
reactions presented that smokers appeared significantly lower levels of factor VIII 
than never smokers (Wannamethee et al., 2005 ; Viel et al., 2007). Zabala and 
Guzzetta, (2015) noticed that secondary erythrocytosis is associated with 
physiological response purposed to elevation in the whole blood viscosity and 
decrease in plasma volume leading to a marked deficiencies in numerous coagulation 
proteins including clotting factors. 
Because of  FVIII is consider an acute-phase reactant, its plasma levels may be 
transiently influenced by different status, including inflammation  (Reitsma et al., 
2003). In addition, other researches had explained that the possible effect of 
inflammation on clotting factors disorder in all smokers and  indicated that plasma 
factor VIII levels did not vary when matched with nonsmokers (Tapson, 2005). 
The present data disagree with the previous study that explained the effect of 
smoking on the coagulation reactions presenting elevated concentration of factor VIII, 
prothrombin, factor XI, peptide and factor X peptide in smoker people (Miller et al., 
1998). It is possible to suggest that smoking may influence liver function to 
synthesize FVIII or because of oxidative stress that initiates deterioration effects on 
clotting factors indicating a fall in the levels of  FVIII. 
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